The Combination of the Low Immunohistochemical Expression of Peroxiredoxin 4 and Perilipin 2 Predicts Longer Survival in Pancreatic Ductal Adenocarcinoma with Peroxiredoxin 4 Possibly Playing a Main Role

Overview

Journal Histol Histopathol

Specialties Anatomy & Histology
Pathology

Date 2023 Oct 3

PMID 37787446

Authors

Jia Han

Tohru Itoh

Akihiro Shioya

Masaru Sakurai

Takeru Oyama

Motona Kumagai

Hiroyuki Takamura

Masashi Okuro

Tsuyoshi Mukai

Hidekazu Kitakata

Masaru Inagaki

Michiyo Higashi

Xin Guo

Sohsuke Yamada

Affiliations

Soon will be listed here.

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is a fatal disease with poor prognosis. Therefore, indicators that can be used for the early prediction of the prognosis of PDAC are needed. Peroxiredoxin (PRDX) 4 is a secretion-type antioxidant enzyme located in the cytoplasmic endoplasmic reticulum. Recent studies have reported that it is closely related to the development and prognosis of many types of cancer. Perilipin (PLIN) 2 is a lipid droplet coating protein. The high expression of PLIN2 is known to be an indicator of some types of cancer and oxidative stress management. It is highly suggestive of the interplay between PRDX4 and PLIN2 to some degree. In this study, we collected 101 patients' clinical data and paraffin-embedded specimens with PDAC and analyzed them with immunohistochemical staining of PRDX4 and PLIN2. We found that the low expression of PRDX4 predicts longer survival and a better clinical condition in PDAC patients. Moreover, when the low expression of PRDX4 is combined with the low expression of PLIN2, the 3-year survival is significantly improved. Univariate and multivariate Cox proportional hazard analyses showed that the PRDX4 expression in PDAC was an independent prognostic factor for survival. Taken together, between PRDX4 and PLIN2, PRDX4 plays a main role in prognosis and has the potential to become a clinical prognostic indicator of PDAC.

Citing Articles

The immunohistochemical combination of low SGLT2 expression and high PRDX4 expression independently predicts shortened survival in patients undergoing surgical resection for hepatoblastoma.

Liu Y, Han J, Shioya A, Zhang Y, Dung V, Oyama T Diagn Pathol. 2025; 20(1):2.

PMID: 39773476 PMC: 11708186. DOI: 10.1186/s13000-025-01596-4.

Clinical pathological significance and biological function of PLIN1 in hepatocellular carcinoma: bioinformatics analysis and in vitro experiments.

Huang J, Wei Y, Fang Z, Yu C, Zhang R, Feng Z BMC Cancer. 2024; 24(1):1073.

PMID: 39215210 PMC: 11363539. DOI: 10.1186/s12885-024-12842-1.

References

Azukisawa S, Zheng J, Guo X, Ura H, Niida Y, Itoh T . The differential expression of perilipin-2 in hepatoblastoma and its association with prognosis. Histol Histopathol. 2021; 36(11):1169-1178. DOI: 10.14670/HH-18-371. View

Baghban R, Roshangar L, Jahanban-Esfahlan R, Seidi K, Ebrahimi-Kalan A, Jaymand M . Tumor microenvironment complexity and therapeutic implications at a glance. Cell Commun Signal. 2020; 18(1):59. PMC: 7140346. DOI: 10.1186/s12964-020-0530-4. View

Cao Q, Ruan H, Wang K, Song Z, Bao L, Xu T . Overexpression of PLIN2 is a prognostic marker and attenuates tumor progression in clear cell renal cell carcinoma. Int J Oncol. 2018; 53(1):137-147. PMC: 5958875. DOI: 10.3892/ijo.2018.4384. View

Conte M, Franceschi C, Sandri M, Salvioli S . Perilipin 2 and Age-Related Metabolic Diseases: A New Perspective. Trends Endocrinol Metab. 2016; 27(12):893-903. DOI: 10.1016/j.tem.2016.09.001. View

Fu Y, Zou T, Shen X, Nelson P, Li J, Wu C . Lipid metabolism in cancer progression and therapeutic strategies. MedComm (2020). 2021; 2(1):27-59. PMC: 8491217. DOI: 10.1002/mco2.27. View

Fujii J, Ikeda Y, Kurahashi T, Homma T . Physiological and pathological views of peroxiredoxin 4. Free Radic Biol Med. 2015; 83:373-9. DOI: 10.1016/j.freeradbiomed.2015.01.025. View

Gao L, Meng J, Yue C, Wu X, Su Q, Wu H . Integrative analysis the characterization of peroxiredoxins in pan-cancer. Cancer Cell Int. 2021; 21(1):366. PMC: 8272277. DOI: 10.1186/s12935-021-02064-x. View

Giguere P, Turcotte M, Hamelin E, Parent A, Brisson J, Laroche G . Peroxiredoxin-4 interacts with and regulates the thromboxane A(2) receptor. FEBS Lett. 2007; 581(20):3863-8. DOI: 10.1016/j.febslet.2007.07.011. View

10.

Guo X, Noguchi H, Ishii N, Homma T, Hamada T, Hiraki T . The Association of Peroxiredoxin 4 with the Initiation and Progression of Hepatocellular Carcinoma. Antioxid Redox Signal. 2018; 30(10):1271-1284. DOI: 10.1089/ars.2017.7426. View

11.

Abdel Hadi N, Reyes-Castellanos G, Carrier A . Targeting Redox Metabolism in Pancreatic Cancer. Int J Mol Sci. 2021; 22(4). PMC: 7913542. DOI: 10.3390/ijms22041534. View

12.

Hashimoto Y, Ishida M, Ryota H, Yamamoto T, Kosaka H, Hirooka S . Adipophilin expression is an indicator of poor prognosis in patients with pancreatic ductal adenocarcinoma: An immunohistochemical analysis. Pancreatology. 2019; 19(3):443-448. DOI: 10.1016/j.pan.2019.03.001. View

13.

Hermann P, Sainz Jr B . Pancreatic cancer stem cells: A state or an entity?. Semin Cancer Biol. 2018; 53:223-231. DOI: 10.1016/j.semcancer.2018.08.007. View

14.

Huang Y, Zhu D, Chen X, Chen Q, Luo Z, Liu C . Curcumin enhances the effects of irinotecan on colorectal cancer cells through the generation of reactive oxygen species and activation of the endoplasmic reticulum stress pathway. Oncotarget. 2017; 8(25):40264-40275. PMC: 5522238. DOI: 10.18632/oncotarget.16828. View

15.

Hwang J, Song J, Yu D, Kim H, Park H, Park Y . Peroxiredoxin 4 as an independent prognostic marker for survival in patients with early-stage lung squamous cell carcinoma. Int J Clin Exp Pathol. 2015; 8(6):6627-35. PMC: 4525878. View

16.

Jain P, Dvorkin-Gheva A, Mollen E, Malbeteau L, Xie M, Jessa F . NOX4 links metabolic regulation in pancreatic cancer to endoplasmic reticulum redox vulnerability and dependence on PRDX4. Sci Adv. 2021; 7(19). PMC: 8104867. DOI: 10.1126/sciadv.abf7114. View

17.

Jia W, Chen P, Cheng Y . PRDX4 and Its Roles in Various Cancers. Technol Cancer Res Treat. 2019; 18:1533033819864313. PMC: 6636222. DOI: 10.1177/1533033819864313. View

18.

Karihtala P, Kauppila S, Soini Y, Arja-Jukkola-Vuorinen . Oxidative stress and counteracting mechanisms in hormone receptor positive, triple-negative and basal-like breast carcinomas. BMC Cancer. 2011; 11:262. PMC: 3141776. DOI: 10.1186/1471-2407-11-262. View

19.

Kimura T, Kitada S, Uramoto H, Zhi L, Kawatsu Y, Takeda T . The combination of strong immunohistochemical mtTFA expression and a high survivin index predicts a shorter disease-specific survival in pancreatic ductal adenocarcinoma. Histol Histopathol. 2014; 30(2):193-204. DOI: 10.14670/HH-30.193. View

20.

Leitner N, Hlavaty J, Ertl R, Gabner S, Fuchs-Baumgartinger A, Walter I . Lipid droplets and perilipins in canine osteosarcoma. Investigations on tumor tissue, 2D and 3D cell culture models. Vet Res Commun. 2022; 46(4):1175-1193. PMC: 9684256. DOI: 10.1007/s11259-022-09975-8. View

21.

Li S, Wu T, Lu Y, Wang J, Yu F, Yang M . Obesity promotes gastric cancer metastasis via diacylglycerol acyltransferase 2-dependent lipid droplets accumulation and redox homeostasis. Redox Biol. 2020; 36:101596. PMC: 7276427. DOI: 10.1016/j.redox.2020.101596. View